Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Stock Transaction
SEC Form 4 Filing
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports the withholding of 362 common stock shares to cover tax obligations arising from vesting restricted stock units.
Summary
- On May 23, 2024, Gao Hanlin, the Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), had 362 shares of common stock withheld to satisfy tax obligations.
- These obligations arose from the vesting of restricted stock units granted on February 23, 2023.
- The shares were withheld at a price of $21.14 per share.
- Following this transaction, Gao Hanlin beneficially owns 927,370 shares of Fulgent Genetics common stock.
Sentiment
Score: 5
Explanation: This is a neutral event related to tax obligations and executive compensation. It doesn't indicate positive or negative sentiment towards the company.
Industry Context
This is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies. It doesn't necessarily reflect a change in the company's outlook or strategy.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine tax-related event for an executive.
Key Dates
| Date | Description |
|---|---|
| February 23, 2023 | Date of grant of restricted stock units to Gao Hanlin. |
| February 27, 2023 | Original Form 4 filing date for the restricted stock unit grant. |
| May 23, 2024 | Date of the stock transaction (tax withholding). |
| May 28, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.